Ekso Bionics Q3 revenue up 38% to $4.6M; net loss narrows to $0.24/share

EKSO BIONICS HOLDINGS, INC.

2023-Q3 EPS reported -$0.88 revenue$13,432,000

Revenue of $4.6M, up 38% YoY; gross margin improved to 53% from 51%.
Net loss narrowed to $3.4M ($0.24 per share) from $4.3M ($0.33) in Q3 2022.
Sold 41 EksoHealth devices, including a record quarter of EVO unit sales.
Cash on hand $9.9M at Sep 30, 2023, down from $20.5M at Dec 31, 2022.
Company applied for CMS code determination for Indego Personal exoskeleton.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EKSO BIONICS HOLDINGS, INC. reported financial results for the three and nine months ended September 30, 2023.

Period: the three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On October 26, 2023 Ekso Bionics Holdings, Inc. (the “Company”) reported its financial results for the three and nine months ended September 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-029094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.